Innovative drugs enter intensive catalyst cycle; Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) surges over 4% in afternoon trading

NewTimeSpace News：On April 15, the innovative drug concept continued to strengthen in afternoon trading, with the Hang Seng Biotech Index climbing 3.98% intraday. Among constituents,3SBiosurged over 8%,Akesojumped more than 6%, whileAscentage Pharma-B,Kelun-Biotech-BandInnovent Biologicsfollowed upward. Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK)rallied over 4% in the afternoon session.

HKEX data shows Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK), issued by ChinaAMC (Hong Kong) Limited, is the first ETF in Hong Kong tracking the Hang Seng Hong Kong-Listed Biotech Index, possessing first-mover advantages and filling a market gap. In the biotech sector—particularly for Hong Kong-listed biotech companies—this product offers uniqueness and scarcity. The index's top ten constituents include industry leaders such asWuXi Biologics,BeiGene, andInnovent Biologics. Most have established solid domestic market shares and demonstrated global competitiveness through sustained R&D investment and overseas licensing partnerships.

According toNextPharmadatabase statistics, this year's innovative drug outboundBD (business development)transactions are noticeably concentrated in early-stage R&D. As preclinical projects and technology platform collaborations increase, the acquired funding is expected to gradually convert into R&D and production orders for preclinical CROs, clinical CROs and CDMOs, driving theCXO sectortoward an upturn in order volume and pricing.

On the news front, the2026 American Association for Cancer Research (AACR) Annual Meetingwill convene from April 17-22, representing one of the most critical data release windows for global oncology innovative drugs. This year,104 Chinese pharmaceutical companiesare participating, showcasing over250 novel drug candidatesand nearly400 cutting-edge research achievements, including92 ADC drugscovering hot targets such as HER2 and Trop2, alongside66 small-molecule assetsand frontier technologies including radiopharmaceuticals and cell therapies. The upcomingASCO meetingin May will provide continuous momentum, forming an intensive catalyst cycle.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.